S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
NASDAQ:ABCL

AbCellera Biologics (ABCL) Stock Price, News & Analysis

$5.05
0.00 (0.00%)
(As of 03/1/2024 ET)
Today's Range
$5.00
$5.26
50-Day Range
$4.81
$5.97
52-Week Range
$3.87
$8.48
Volume
1.41 million shs
Average Volume
1.70 million shs
Market Capitalization
$1.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.86

AbCellera Biologics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
214.0% Upside
$15.86 Price Target
Short Interest
Bearish
11.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of AbCellera Biologics in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.64) to ($0.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

Medical Sector

676th out of 952 stocks

Pharmaceutical Preparations Industry

313th out of 432 stocks


ABCL stock logo

About AbCellera Biologics Stock (NASDAQ:ABCL)

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ABCL Stock Price History

ABCL Stock News Headlines

AbCellera: Victim Of Its Own Success
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Piper Sandler Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
AbCellera Announces Resignation of Board Member
ABCL Mar 2024 4.000 call
ABCL Mar 2024 5.000 call
AbCellera Biologics (NASDAQ:ABCL) Upgraded to "Buy" by Benchmark
Stifel Nicolaus Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
Q4 2023 Abcellera Biologics Inc Earnings Call
Recap: AbCellera Biologics Q4 Earnings
AbCellera Reports Full Year 2023 Business Results
See More Headlines
Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/03/2023
Today
3/02/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ABCL
Fax
N/A
Employees
630
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.86
High Stock Price Target
$24.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+214.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-146,400,000.00
Net Margins
-384.99%
Pretax Margin
-457.67%

Debt

Sales & Book Value

Annual Sales
$38.03 million
Book Value
$3.94 per share

Miscellaneous

Free Float
197,774,000
Market Cap
$1.48 billion
Optionable
Optionable
Beta
0.38
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Carl L.G. Hansen Ph.D. (Age 49)
    CEO, President & Chairperson
    Comp: $711.47k
  • Mr. Andrew Booth M.B.A. (Age 50)
    Chief Financial Officer
    Comp: $642.42k
  • Dr. Veronique Lecault Ph.D. (Age 39)
    COO & Director
    Comp: $645.07k
  • Mr. Tryn T. Stimart Esq. (Age 54)
    J.D., Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
    Comp: $644.4k
  • Mr. Neil Aubuchon M.B.A. (Age 54)
    Chief Commercial Officer
    Comp: $684.81k
  • Marcie Thiessen CPA
    CGA, Senior Director of Finance & Accounting
  • Dr. Ester Falconer Ph.D. (Age 49)
    Chief Technology Officer
  • Josephine Hellschlienger Ph.D.
    Manager of Investor Relations
  • Kathleen Reid B.A.
    Head of Corporate Communications
  • Graham Craig M.Sc.
    Director of Corporate Development














ABCL Stock Analysis - Frequently Asked Questions

Should I buy or sell AbCellera Biologics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABCL shares.
View ABCL analyst ratings
or view top-rated stocks.

What is AbCellera Biologics' stock price target for 2024?

7 brokers have issued twelve-month price objectives for AbCellera Biologics' stock. Their ABCL share price targets range from $6.00 to $24.00. On average, they expect the company's share price to reach $15.86 in the next year. This suggests a possible upside of 214.0% from the stock's current price.
View analysts price targets for ABCL
or view top-rated stocks among Wall Street analysts.

How have ABCL shares performed in 2024?

AbCellera Biologics' stock was trading at $5.71 on January 1st, 2024. Since then, ABCL shares have decreased by 11.6% and is now trading at $5.05.
View the best growth stocks for 2024 here
.

Are investors shorting AbCellera Biologics?

AbCellera Biologics saw a decrease in short interest during the month of February. As of February 15th, there was short interest totaling 22,810,000 shares, a decrease of 6.9% from the January 31st total of 24,490,000 shares. Based on an average trading volume of 1,560,000 shares, the days-to-cover ratio is currently 14.6 days. Approximately 11.4% of the shares of the company are sold short.
View AbCellera Biologics' Short Interest
.

When is AbCellera Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ABCL earnings forecast
.

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. The firm earned $10.10 million during the quarter, compared to analyst estimates of $12.38 million. AbCellera Biologics had a negative net margin of 384.99% and a negative trailing twelve-month return on equity of 12.36%. AbCellera Biologics's revenue for the quarter was down 78.0% compared to the same quarter last year. During the same period last year, the company earned ($0.02) EPS.

What ETFs hold AbCellera Biologics' stock?

ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ).

When did AbCellera Biologics IPO?

(ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at a price of $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.

Who are AbCellera Biologics' major shareholders?

AbCellera Biologics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (8.29%), Capital World Investors (2.88%), Federated Hermes Inc. (1.07%), FIL Ltd (0.65%), Norges Bank (0.32%) and Intellectus Partners LLC (0.31%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault.
View institutional ownership trends
.

How do I buy shares of AbCellera Biologics?

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABCL) was last updated on 3/2/2024 by MarketBeat.com Staff